Patient View Survey

Dear Members, You might have received a mail from PatientView, seeking input to their study on the corporate reputation of the pharmaceutical industry in 2015โ€” from the perspective of patient groups. We also know that some of you have not received it, and would be interested in taking part. We therefore relay the information so […]

Patient stories…

Our first patient stories have arrived in our inbox. What a treat to read and something we look forward to sharing with you all in the near future. We are still looking for further contributions so, if you’re wondering what to do with all that spare time over the holidays (and beyond), don’t worry, the […]

EPF news

Input is being sought from European Patients’ Forum members on the Patient Empowerment Charter. The deadline for feedback is 10th January 2016. For more information please click here. The European Patients’ Forum has also put together its draft position paper on Cross Border Healthcare. Feedback is invited from member groups. More information here.    

Patient Panel dates set

The final dates have been set for the Patient Panel. The Patient Panel is seeking participants and will take place in Brussels from March 11-13th 2016. This is a rare and unique opportunity for patients to participate in a truly worthwhile experience. All costs, travel, accommodation and meals are reimbursed. For further information, please click […]

LupuzorTM enters phase III

LupuzorTM enters phase III Press release from the CNRS Paris, 15 December 2015 LupuzorTM may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable. Discovered by Sylviane Muller’s team in the CNRS Immunopathologie et Chimie Thรฉrapeutique laboratory, in Strasbourg, this peptide is the subject of a CNRS […]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!

Don't forget to subscribe to be up to date!

www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
... See MoreSee Less

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the Info Centre section of our website! 

Dont forget to subscribe to be up to date!

https://www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
7 days ago
LUPUS EUROPE

No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.

Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Letโ€™s fight the daily battle together.
... See MoreSee Less

1 week ago
LUPUS EUROPE

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. ๐Ÿงก

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Letโ€™s work together and lift each other up.
... See MoreSee Less

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. ๐Ÿงก

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Letโ€™s work together and lift each other up.
2 weeks ago
LUPUS EUROPE

Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.

Belimumab is the first treatment specifically approved for lupus in more than 50 years.

You can read more about it, plus the results of the phase II, in the link from MedPage Today ๐Ÿ‘‡

www.medpagetoday.com/rheumatology/lupus/99927
... See MoreSee Less

Comment on Facebook

๐Ÿ’œ

Yes!!!!!!

nu hopen dat Nederland artsen dit overneemt๐Ÿค”

So happy to hear this

Brilliant

View more comments